Effects of alendronate and pamidronate on cultured rat metatarsal bones: Failure to prevent dexamethasone-induced growth retardation

Bone

Volumn 42, Issue 4, 2008, Pages 702-709

  Heino, Terhi J ^a   Chagin, Andrei S ^a   Takigawa, Masaharu ^b   Sävendahl, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Bisphosphonates; Bone growth; Chondrocytes; Glucocorticoids; Proliferation

Indexed keywords

ALENDRONIC ACID; BROXURIDINE; COLLAGEN TYPE 10; DEXAMETHASONE; PAMIDRONIC ACID;

APOPTOSIS; ARTICLE; BONE GROWTH; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS; GROWTH RETARDATION; HUMAN; HUMAN CELL; METATARSAL BONE; NICK END LABELING; NONHUMAN; RAT; TREATMENT FAILURE;

ALENDRONATE; ANIMALS; BONE DENSITY; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CHONDROCYTES; CYTOPROTECTION; DEXAMETHASONE; DIPHOSPHONATES; FOOT BONES; HUMANS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE CULTURE TECHNIQUES;

EID: 40849135488     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.01.001     Document Type: Article

References (43)

1. Acott P.D., Wong J.A., Lang B.A., and Crocker J.F. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol 20 (2005) 368-373
2. Allen D.B. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am 25 (1996) 699-717
3. Amin S., Lavalley M.P., Simms R.W., and Felson D.T. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 17 (2002) 1512-1526
4. Bianchi M.L., Cimaz R., Bardare M., Zulian F., Lepore L., Boncompagni A., et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 43 (2000) 1960-1966
5. Brumsen C., Hamdy N.A., and Papapoulos S.E. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76 (1997) 266-283
6. Camacho N.P., Raggio C.L., Doty S.B., Root L., Zraick V., Ilg W.A., et al. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 69 (2001) 94-101
7. Chagin A.S., Chrysis D., Takigawa M., Ritzen E.M., and Savendahl L. Locally produced estrogen promotes fetal rat metatarsal bone growth; an effect mediated through increased chondrocyte proliferation and decreased apoptosis. J Endocrinol 188 (2006) 193-203
8. Chagin A.S., Karimian E., Zaman F., Takigawa M., Chrysis D., and Savendahl L. Tamoxifen induces permanent growth arrest through selective induction of apoptosis in growth plate chondrocytes in cultured rat metatarsal bones. Bone 40 (2007) 1415-1424
9. Chrysis D., Ritzen E.M., and Savendahl L. Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes. J Endocrinol 176 (2003) 331-337
10. Chrysis D., Zaman F., Chagin A.S., Takigawa M., and Savendahl L. Dexamethasone induces apoptosis in proliferative chondrocytes through activation of caspases and suppression of the Akt-phosphatidylinositol 3′-kinase signaling pathway. Endocrinology 146 (2005) 1391-1397
11. De Luca F., Barnes K.M., Uyeda J.A., De-Levi S., Abad V., Palese T., et al. Regulation of growth plate chondrogenesis by bone morphogenetic protein-2. Endocrinology 142 (2001) 430-436
12. DiMeglio L.A., and Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 21 (2006) 132-140
13. Evans K.D., Lau S.T., Oberbauer A.M., and Martin R.B. Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta. Bone 32 (2003) 268-274
14. Glorieux F.H. Bisphosphonate therapy for severe osteogenesis imperfecta. J Pediatr Endocrinol Metab 13 Suppl 2 (2000) 989-992
15. Heikkila P., Teronen O., Moilanen M., Konttinen Y.T., Hanemaaijer R., Laitinen M., et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 13 (2002) 245-254
16. Itoh F., Aoyagi S., Furihata-Komatsu H., Aoki M., Kusama H., Kojima M., et al. Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures. Eur J Pharmacol 477 (2003) 9-16
17. Land C., Rauch F., and Glorieux F.H. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 21 (2006) 374-379
18. Land C., Rauch F., Munns C.F., Sahebjam S., and Glorieux F.H. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 39 (2006) 901-906
19. Lowik C.W., van der Pluijm G., van der Wee-Pals L.J., van Treslong-De Groot H.B., and Bijvoet O.L. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res 3 (1988) 185-192
20. Mansfield K., Teixeira C.C., Adams C.S., and Shapiro I.M. Phosphate ions mediate chondrocyte apoptosis through a plasma membrane transporter mechanism. Bone 28 (2001) 1-8
21. Martensson K., Chrysis D., and Savendahl L. Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 19 (2004) 1805-1812
22. McCarthy E.A., Raggio C.L., Hossack M.D., Miller E.A., Jain S., Boskey A.L., et al. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatr Res 52 (2002) 660-670
23. Picherit C., Coxam V., Oudadesse H., Martini B., Gaumet N., Davicco M.J., et al. Dihydrotestosterone prevents glucocorticoid-negative effects on fetal rat metatarsal bone in vitro. Biol Neonate 77 (2000) 181-190
24. Plotkin L.I., Aguirre J.I., Kousteni S., Manolagas S.C., and Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280 (2005) 7317-7325
25. Plotkin L.I., Manolagas S.C., and Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39 (2006) 443-452
26. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., and Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104 (1999) 1363-1374
27. Rauch F., Cornibert S., Cheung M., and Glorieux F.H. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40 (2007) 821-827
28. Rauch F., Munns C., Land C., and Glorieux F.H. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 91 (2006) 1268-1274
29. Rodan G.A. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 38 (1998) 375-388
30. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9 (2003) 2643-2658
31. Rudge S., Hailwood S., Horne A., Lucas J., Wu F., and Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 44 (2005) 813-818
32. Russell R.G. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 1068 (2006) 367-401
33. Seikaly M.G., Kopanati S., Salhab N., Waber P., Patterson D., Browne R., et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 25 (2005) 786-791
34. Takigawa M., Tajima K., Pan H.O., Enomoto M., Kinoshita A., Suzuki F., et al. Establishment of a clonal human chondrosarcoma cell line with cartilage phenotypes. Cancer Res 49 (1989) 3996-4002
35. Twiss I.M., Pas O., Ramp-Koopmanschap W., Den Hartigh J., and Vermeij P. The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. J Bone Miner Res 14 (1999) 784-791
36. Unal E., Abaci A., Bober E., and Buyukgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J Pediatr Endocrinol Metab 19 (2006) 523-528
37. Vaisman D.N., McCarthy A.D., and Cortizo A.M. Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. Biol Trace Elem Res 104 (2005) 131-140
38. Van Offel J.F., Schuerwegh A.J., Bridts C.H., Stevens W.J., and De Clerck L.S. Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann Rheum Dis 61 (2002) 925-928
39. Waterhouse K.M., Auron A., Srivastava T., Haney C., and Alon U.S. Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children. Pediatr Nephrol 22 (2007) 282-287
40. Widler L., Jaeggi K.A., Glatt M., Muller K., Bachmann R., Bisping M., et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 45 (2002) 3721-3738
41. Wiernikowski J.T., Barr R.D., Webber C., Guo C.Y., Wright M., and Atkinson S.A. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study. J Oncol Pharm Pract 11 (2005) 51-56
42. Wu S., Palese T., Mishra O.P., Delivoria-Papadopoulos M., and De Luca F. Effects of Ca2+ sensing receptor activation in the growth plate. FASEB J 18 (2004) 143-145
43. Zeitlin L., Rauch F., Plotkin H., and Glorieux F.H. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111 (2003) 1030-1036